Sacroiliac joint bone tissue (SIJ bone tissue)

The sacroiliac joint (SIJ) bone tissue comprises the articular surfaces of the sacrum and the ilium, which are essential for transferring mechanical loads from the axial skeleton to the lower extremities (StatPearls, 2023). This tissue is characterized by a combination of hyaline and fibrocartilage supported by dense subchondral bone that provides structural integrity and stability to the pelvic girdle (NCBI, 2022). In pathological states such as axial spondyloarthritis or sacroiliitis, this bone tissue becomes a primary site of immune-mediated inflammation, leading to bone marrow edema, erosions, and eventually syndesmophyte formation or ankylosis (PubMed, 2018). While the tissue itself is an anatomical structure rather than a single molecular target, it serves as the clinical focus for therapies targeting inflammatory mediators like Tumor Necrosis Factor (TNF) and Interleukin-17 (IL-17) (NIH, 2023). Pharmacological management often involves nonsteroidal anti-inflammatory drugs (NSAIDs) for symptom relief and biologic disease-modifying antirheumatic drugs (bDMARDs) to modify disease progression and preserve the structural integrity of the joint (Mayo Clinic, 2023).

Other names

Sacroiliac joint boneSI joint boneArticular surfaces of the sacroiliac jointSacral and iliac subchondral bone

Inhibition of pro-inflammatory cytokines such as Tumor Necrosis Factor (TNF) and Interleukin-17A (IL-17A) to reduce inflammation and bone remodeling in the joint; inhibition of cyclooxygenase (COX) enzymes to alleviate pain and inflammation.